Indications et mécanismes d’action des immunoglobulines intraveineuses dans les pathologies auto-immunes et inflammatoires systémiques (Q58861264)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

review article

1 reference

title

[Indications and mechanisms of action of the intravenous immunoglobulines in the systemic autoimmune and inflammatory pathologies] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

L Mouthon

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

G Bussone

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

1 December 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

Revue de Médecine Interne

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

12 Suppl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

H14-20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin

14 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

[Immunomodulatory effects of intravenous immunoglobulins]

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Appropriate number of plasma exchanges in Guillain-Barré syndrome. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Intravenous immunoglobulin for multifocal motor neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Treatment of Myasthenia Gravis Exacerbation With Intravenous Immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

High-Dose Intravenous Immune Globulin for Stiff-Person Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

A randomized double-blind trial of intravenous immunoglobulin for pemphigus

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Treatment of refractory immune thrombocytopenic purpura with an anti-Fc gamma-receptor antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Identification of a receptor required for the anti-inflammatory activity of IVIG.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Complement interaction with immune serum globulin and immune globulin intravenous

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Effect of whole and fractionated intravenous immunoglobulin on complement in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Intravenous immunoglobulin (IVIG) attenuates antibody binding in acute haemorrhagic immunopneumonitis in a rat model of complement-dependent lung injury

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Plasma C3c changes in myasthenia gravis patients receiving high-dose intravenous immunoglobulin during crisis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Effects of immunoglobulin and gamma-interferon on the production of tumour necrosis factor-alpha and interleukin-1 beta by peripheral blood monocytes in the acute phase of Kawasaki disease

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Immunoglobulins induce increased myelin debris clearance by mouse macrophages.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Inhibition of IgE production in vitro by intact and fragmented intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg)

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Identification of target antigens of self-reactive IgG in intravenous immunoglobulin preparations

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0248-8663%2809%2973168-6

7 January 2021

10.1016/S0248-8663(09)73168-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19995651%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference